Benjamin Rossi

Pito Chickering

Benjamin Hendrix

Brian Tanquilut

Meghan Holtz

Andrew Mok

Ben Hendrix

David Macdonald

Grayson Joshua McAlister

Grayson McAlister

Kieran Ryan

Michael Murray

Raj Kumar

Scott Fidel

- Aveanna Healthcare Holdings Inc. announced the pricing of a secondary offering of **10,000,000 shares** of its common stock at a public offering price of **$9.00 per share**.  **[1832332_1fe05c50811f4c29aad045f69e0e0a55_0]** 
- The offering is being conducted by certain selling stockholders affiliated with J.H. Whitney Equity Partners VII, LLC.  **[1832332_1fe05c50811f4c29aad045f69e0e0a55_0]** 
- Aveanna Healthcare Holdings Inc. **is not offering any shares** and **will not receive any proceeds** from the sale of shares in this offering.  **[1832332_1fe05c50811f4c29aad045f69e0e0a55_0]** 
- The selling stockholders have granted the underwriters a 30-day option to purchase up to an additional **1,500,000 shares**.  **[1832332_1fe05c50811f4c29aad045f69e0e0a55_0]** 
- The offering is expected to settle on **October 23, 2025**.  **[1832332_1fe05c50811f4c29aad045f69e0e0a55_0]**

Aveanna Healthcare Holdings Announces Pricing of Secondary Offering

- Aveanna Healthcare Holdings Inc. (AVAH) expects to report preliminary **revenue** of approximately **$616 million to $624 million** for the three-month period ended September 27, 2025.  **[1832332_115dfdb864bf40a09a85069ae347afe5_0]** 
- For the same period, preliminary **net income** is anticipated to be between **$11 million and $15 million**, and **Adjusted EBITDA** is expected to range from **$77 million to $81 million**.  **[1832332_115dfdb864bf40a09a85069ae347afe5_0]** 
- These preliminary Q3 2025 results indicate strong year-over-year growth, with revenue increasing by approximately **21.0% to 22.6%**, net income by **125.7% to 135.0%**, and Adjusted EBITDA by **61.0% to 69.3%**.  **[1832332_115dfdb864bf40a09a85069ae347afe5_0]**

Aveanna Healthcare Holdings Announces Preliminary Third Quarter 2025 Financial Results

- Aveanna Healthcare Holdings Inc. (AVAH) announced **preliminary financial results** for the **three-month period ended September 27, 2025**.  **[1832332_0001193125-25-245131_avah-20251021.htm:0]** **[1832332_0001193125-25-245131_avah-ex99_1.htm:0]** 
- The company expects to report revenue of approximately **$616 million to $624 million**, representing growth of approximately **21.0% to 22.6%** over the prior year's third quarter.  **[1832332_0001193125-25-245131_avah-ex99_1.htm:0]** 
- **Net income** is anticipated to be between **$11 million and $15 million**, reflecting growth of approximately **125.7% to 135.0%** over the prior year's third quarter.  **[1832332_0001193125-25-245131_avah-ex99_1.htm:0]** 
- **Adjusted EBITDA** is expected to be approximately **$77 million to $81 million**, an increase of approximately **61.0% to 69.3%** from the prior year's third quarter.  **[1832332_0001193125-25-245131_avah-ex99_1.htm:0]** 
- These financial results are **preliminary estimates** and are subject to the completion of financial closing procedures and potential adjustments.  **[1832332_0001193125-25-245131_avah-ex99_1.htm:0]**

Aveanna Healthcare Holdings Announces Preliminary Q3 2026 Financial Results

- Aveanna Healthcare Holdings (AVAH) is halfway through a three-year transformation strategy, leading to accelerated organic growth across its businesses.  **[1832332_2162788_0]**  A recent successful refinancing lowered the total cost of capital by over **$14 million annually** and provided **seven years of capital structure stability**.  **[1832332_2162788_0]** **[1832332_2162788_8]** 
- The company projects a long-term internal organic growth algorithm of **5% to 7%**, supplemented by **2% to 4%** from tuck-in M&A, aiming for a total growth rate of **10% to 11%**.  **[1832332_2162788_1]**  Current year-over-year growth is approximately **16%**, partly driven by the Thrive acquisition.  **[1832332_2162788_1]** 
- A "preferred payer strategy" is being successfully implemented, with **55% of Private Duty Services (PDS) volumes** now with preferred payers, targeting **75% to 80%**.  **[1832332_2162788_3]**  This strategy is expected to maintain PDS gross margins in the **27-28% range**.  **[1832332_2162788_4]** 
- Deleveraging is a key strategic focus, with current leverage around **five times** and a clear path to **sub four**.  **[1832332_2162788_8]**  The company plans **one to two tuck-in acquisitions per year**, targeting PDS businesses at **high single digits (sub 10x)** pre-synergy and Home Health at **five to seven times**.  **[1832332_2162788_8]** **[1832332_2162788_9]**

Aveanna Healthcare Holdings Outlines Growth Strategy and Financial Improvements

- Aveanna Healthcare Holdings Inc. reported strong **Q2 2025 financial results**, with **revenue increasing 16.8% year-over-year to $589.6 million** and **Adjusted EBITDA growing 93.6% year-over-year to $88.3 million**.  **[1832332_0001193125-25-223435_avah-ex99_1.htm:10]** 
- The company provided **FY2025 guidance** (as of Q2 2025), projecting **revenue greater than $2.3 billion** and **Adjusted EBITDA exceeding $270 million**.  **[1832332_0001193125-25-223435_avah-ex99_1.htm:7]** 
- Aveanna executed a **comprehensive debt refinancing in September 2025**, extending maturities to **2032** and significantly reducing interest expense.  **[1832332_0001193125-25-223435_avah-ex99_1.htm:10]** 
- As of Q2 2025, the company maintained **liquidity of $456.9 million** and reported **YTD 2025 operating cash flow of $42.9 million** and **free cash flow of $36.9 million**.  **[1832332_0001193125-25-223435_avah-ex99_1.htm:10]**

Aveanna Healthcare Holdings Inc. Reports Q2 2025 Financial Performance and Provides FY2025 Guidance

- Aveanna Healthcare Holdings Inc. announced the closing of its refinanced first lien credit facility on **September 18, 2025**, which involved the refinancing of **$886.0 million** in existing first lien term loans and an additional borrowing of **$439.0 million** in incremental first lien term loans.  **[1832332_0001193125-25-206824_avah-ex99_1.htm:0]** 
- The company also upsized its revolving credit facility from **$170.3 million** to **$250.0 million** of maximum availability.  **[1832332_0001193125-25-206824_avah-ex99_1.htm:0]** **[1832332_0001193125-25-206824_avah-ex10_1.htm:13]** 
- The maturity dates for the combined **$1.325 billion** first lien term loans were extended to **2032**, and the revolving credit facility's maturity date was extended from **2028** to **2030**.  **[1832332_0001193125-25-206824_avah-ex99_1.htm:0]** 
- Proceeds from the incremental first lien term loans were used to repay in full the existing second lien term loans, amounting to **$415.0 million**, resulting in the termination of the second lien term loan facility.  **[1832332_0001193125-25-206824_avah-ex99_1.htm:0]** **[1832332_0001193125-25-206824_avah-20250917.htm:2]**